Guangdong Taienkang Pharmaceutical Co., Ltd. (SHE:301263)

SHE:301263 Income Statement

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Mar 31, 2025	Dec 31, 2024	Dec 31, 2023	Jan 1, 2023	Jan 1, 2022	Dec 31, 2020
Operating Revenue	715.72	720.17	760.07	782.8	653.65	708.98
Other Revenue	0.86	0.86	0.72	0.68	-	-
Revenue	716.59	721.03	760.79	783.48	653.65	708.98
Revenue Growth (YoY)	-5.23%	-5.23%	-2.90%	19.86%	-7.80%	42.83%
Cost of Revenue	320.27	319.09	303.93	328.67	326.37	320.69
Gross Profit	396.32	401.94	456.85	454.81	327.28	388.29
Selling, General & Admin	213.13	203.97	202.59	211.83	163.4	150.48
Research & Development	84.58	86.42	62.89	40.39	26.46	31.34
Other Operating Expenses	3.45	1.73	3.78	4.35	7.08	7.82
Operating Expenses	301.64	291.88	273.14	260.03	199.77	196.45
Operating Income	94.67	110.06	183.71	194.78	127.5	191.84
Interest Expense	-9.11	-8.63	-1.7	-2.58	-4.72	-5.14
Interest & Investment Income	9.41	9.51	16.48	19.13	0.87	1.11
Currency Exchange Gain (Loss)	-2.3	-2.3	-0.88	-4.34	0.53	0.43
Other Non Operating Income (Expenses)	1.09	-0.16	-0.12	-0.11	-0.25	-0.4
EBT Excluding Unusual Items	93.76	108.48	197.49	206.88	123.93	187.84
Gain (Loss) on Sale of Investments	-1.03	0.1	0.8	0.65	-	-
Gain (Loss) on Sale of Assets	-0.87	-	0.15	0.01	-0.02	-0.51
Asset Writedown	-1.15	-1.27	-7.61	-0.3	-0.5	-1.3
Other Unusual Items	-1.4	-1.74	1.5	0.12	14.14	11.52
Pretax Income	89.31	105.57	192.32	207.35	137.54	197.55
Income Tax Expense	4.01	8.53	38.82	32.75	17.55	43.85
Earnings From Continuing Operations	85.3	97.04	153.5	174.6	120	153.7
Minority Interest in Earnings	9	11.18	6.7	0.01	0.07	7.12
Net Income	94.3	108.22	160.2	174.61	120.07	160.83
Net Income to Common	94.3	108.22	160.2	174.61	120.07	160.83
Net Income Growth	-38.64%	-32.45%	-8.25%	45.43%	-25.34%	192.92%
Shares Outstanding (Basic)	426	416	422	397	318	298
Shares Outstanding (Diluted)	426	416	422	397	318	298
Shares Change (YoY)	2.15%	-1.27%	6.23%	24.87%	6.49%	5.67%
EPS (Basic)	0.22	0.26	0.38	0.44	0.38	0.54
EPS (Diluted)	0.22	0.26	0.38	0.44	0.38	0.54
EPS Growth	-39.93%	-31.58%	-13.64%	16.46%	-29.89%	177.21%
Free Cash Flow	-5.65	20.78	-106.48	58.94	75.38	32.41
Free Cash Flow Per Share	-0.01	0.05	-0.25	0.15	0.24	0.11
Dividend Per Share	0.200	0.200	0.300	0.389	0.194	-
Dividend Growth	-33.33%	-33.33%	-22.86%	100.05%	-	-
Gross Margin	55.31%	55.74%	60.05%	58.05%	50.07%	54.77%
Operating Margin	13.21%	15.26%	24.15%	24.86%	19.51%	27.06%
Profit Margin	13.16%	15.01%	21.06%	22.29%	18.37%	22.68%
Free Cash Flow Margin	-0.79%	2.88%	-14.00%	7.52%	11.53%	4.57%
EBITDA	-	162.46	221.01	226.75	155.09	214.49
EBITDA Margin	-	22.53%	29.05%	28.94%	23.73%	30.25%
D&A For EBITDA	-	52.4	37.3	31.97	27.58	22.65
EBIT	94.67	110.06	183.71	194.78	127.5	191.84
EBIT Margin	13.21%	15.26%	24.15%	24.86%	19.51%	27.06%
Effective Tax Rate	4.49%	8.08%	20.19%	15.79%	12.76%	22.20%
Revenue as Reported	716.59	721.03	760.79	783.48	653.65	708.98
Advertising Expenses	-	65.86	71.69	95.69	61.51	44.68

Updated Oct 28, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.